Non-microbial approach for Helicobacter pylori as faster track to prevent gastric cancer than simple eradication

World Journal of Gastroenterology

Volumn 19, Issue 47, 2013, Pages 8986-8995

  Park, Sang Ho ^a   Kangwan, Napapan ^a   Park, Jong Min ^a   Kim, Eun Hee ^a   Hahm, Ki Baik ^a  

^a CHA University   (South Korea)

Author keywords

Atrophic gastritis; Gastric cancer; Helicobacter pylori; Non microbial approach; Prevention

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTIOXIDANT; ARACHIDONATE 5 LIPOXYGENASE; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 8; LEUKOTRIENE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PLANT MEDICINAL PRODUCT; PROBIOTIC AGENT; PROSTAGLANDIN SYNTHASE; ROFECOXIB; STROMELYSIN; SULFORAPHANE; VALDECOXIB;

APOPTOSIS; BACTERIAL CLEARANCE; BROCCOLI; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); CURCUMA LONGA; DNA DAMAGE; ERYTHROCYTE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIPID RAFT; MESENCHYMAL STEM CELL; MICROFLORA; NONHUMAN; OXIDATIVE STRESS; PHYTONUTRIENT; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER;

ATROPHIC GASTRITIS; GASTRIC CANCER; HELICOBACTER PYLORI; NON-MICROBIAL APPROACH; PREVENTION;

ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; FATTY ACIDS, OMEGA-3; GASTRITIS, ATROPHIC; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PHYTOCHEMICALS; PROBIOTICS; RISK FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84890923699     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i47.8986     Document Type: Review

References (86)

1. Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010; 23: 713-739 [PMID: 20930071 DOI: 10.1128/CMR.00011-10]
2. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241 [PMID: 7715068]
3. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Ca-margo MC, Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54: 1536-1540 [PMID: 15985559 DOI: 10.1136/gut.2005.072009]
4. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194 [PMID: 14722144 DOI: 10.1001/jama.291.2.187]
5. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Heli-cobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
6. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34: 1255-1268 [PMID: 22017749 DOI: 10.1111/j.1365-2036.2011.04887.x]
7. Fujioka T, Aoyama N, Sakai K, Miwa Y, Kudo M, Ka-washima J, Matsubara Y, Miwa J, Yakabi K. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithro-mycin for Helicobacter pylori eradication in Japan. J Gas-troenterol 2012; 47: 276-283 [PMID: 22065160 DOI: 10.1007/s00535-011-0487-6]
8. Dai WQ, Zhou YQ, Xu L, Wang BF, Fan XM, Wu JY, Wang CY, Xu XF, Guo CY. The eradicating Helicobacter pylori infection in duodenal ulcer patients by three short-term triple therapies in China: a multicenter clinical comparative study. Hepatogastroenterology 2012; 59: 296-299 [PMID: 22260837 DOI: 10.5754/hge11241]
9. Karatapanis S, Georgopoulos SD, Papastergiou V, Skorda L, Papantoniou N, Lisgos P, Kouvidou C, Fragkou P, Mentis A. "7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial". Acta Gastroenterol Belg 2011; 74: 407-412 [PMID: 22103045]
10. Mansour NM, Hashash JG, El-Halabi M, Ghaith O, Maasri K, Sukkarieh I, Malli A, Sharara AI. A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2011; 23: 865-870 [PMID: 21811161 DOI: 10.1097/MEG.0b013e3283496502]
11. Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-609 [PMID: 10792124 DOI: 10.1046/j.1365-2036.2000.00744.x]
12. Kim BG, Lee DH, Ye BD, Lee KH, Kim BW, Kim SG, Kim SW, Kim SK, Kim JJ, Kim HY, Park JJ, Park CY, Baik GH, Lee YC, Lee JH, Lee JH, Chun HJ, Hahm KB, Hong SJ, Lee SW, Jung HC. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007; 12: 31-35 [PMID: 17241298 DOI: 10.1111/j.1523-5378.2007.00468.x]
13. Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Mer-rell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol 2011; 49: 987-993 [PMID: 22203563 DOI: 10.1007/ s12275-011-1170-6]
14. Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol 2011; 26: 1457-1461 [PMID: 21679250 DOI: 10.1111/j.1440-1746.2011.06815.x]
15. Kim JY, Kim N, Park HK, Jo HJ, Shin CM, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Nam RH, Kim JM, Lee JH, Jung HC, Song IS. [Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea]. Korean J Gastroenterol 2011; 58: 74-81 [PMID: 21873821 DOI: 10.4166/ kjg.2011.58.2.74]
16. Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38-45 [PMID: 20302588 DOI: 10.1111/ j.1523-5378.2009.00735.x]
17. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clar-ithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013; 88: 33-45 [PMID: 23880479 DOI: 10.1159/000350719]
18. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013; 25: 1134-1140 [PMID: 23778309 DOI: 10.1097/MEG.0b013e3283633b57]
19. Zullo A, De Francesco V, Hassan C, Ridola L, Repici A, Bruzzese V, Vaira D. Modifed sequential therapy regimens for Helicobacter pylori eradication: a systematic review. Dig Liver Dis 2013; 45: 18-22 [PMID: 23022424 DOI: 10.1016/j.dld.2012.08.025]
20. Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH, Tseng PH, Chang L, Chang WH, Wang HP, Shun CT, Wu JY, Lee YC, Lin JT, Wu MS. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Che-mother 2013; 68: 450-456 [PMID: 23099849 DOI: 10.1093/jac/ dks407]
21. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-213 [PMID: 23158886 DOI: 10.1016/S0140-6736(12)61579-7]
22. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36: 2699-2702 [PMID: 1277177]
23. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278: 1073-1077 [PMID: 9353183 DOI: 10.1126/science.278.5340.1073]
24. Chun KS, Kim EH, Lee S, Hahm KB. Chemoprevention of gastrointestinal cancer: the reality and the dream. Gut Liver 2013; 7: 137-149 [PMID: 23560148 DOI: 10.5009/gnl.2013.7.2.137]
25. Park S, Han SU, Lee KM, Park KH, Cho SW, Hahm KB. 5-LOX inhibitor modulates the infammatory responses provoked by Helicobacter pylori infection. Helicobacter 2007; 12: 49-58 [PMID: 17241301 DOI: 10.1111/j.1523-5378.2007.00469.x]
26. Wallace JL, McKnight GW, Keenan CM, Byles NI, Mac-Naughton WK. Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. Gastroenterology 1990; 98: 1178-1186 [PMID: 2157619]
27. Gyömber E, Vattay P, Szabo S, Rainsford KD. Effect of li-poxygenase inhibitors and leukotriene antagonists on acute and chronic gastric haemorrhagic mucosal lesions in ulcer models in the rat. J Gastroenterol Hepatol 1996; 11: 922-927 [PMID: 8912128]
28. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cy-clooxygenase and 5-lipoxygenase. A new avenue in anti-in-fammatory therapy? Biochem Pharmacol 2001; 62: 1433-1438 [PMID: 11728379 DOI: 10.1016/S0006-2952(01)00747-X]
29. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003; 62: 501-509 [PMID: 12759283]
30. Wendum D, Masliah J, Trugnan G, Fléjou JF. Cyclooxygen-ase-2 and its role in colorectal cancer development. Virchows Arch 2004; 445: 327-333 [PMID: 15340847 DOI: 10.1007/ s00428-004-1105-2]
31. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, Mukherjee P. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004; 11: 328-339 [PMID: 14993030 DOI: 10.1245/ASO.2004.05.027]
32. Patel S, Chiplunkar S. Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer. Indian J Biochem Biophys 2007; 44: 419-428 [PMID: 18320840]
33. Ozuysal S, Bilgin T, Ozgur T, Celik N, Evrensel T. Expression of cyclooxygenase-2 in ovarian serous carcinoma: correlation with angiogenesis, nm23 expression and survival. Eur J Gynaecol Oncol 2009; 30: 640-645 [PMID: 20099494]
34. Chen Z, Liu M, Liu X, Huang S, Li L, Song B, Li H, Ren Q, Hu Z, Zhou Y, Qiao L. COX-2 regulates E-cadherin expression through the NF-κB/Snail signaling pathway in gastric cancer. Int J Mol Med 2013; 32: 93-100 [PMID: 23670240 DOI: 10.3892/ijmm.2013.1376]
35. Tseng YC, Tsai YH, Tseng MJ, Hsu KW, Yang MC, Huang KH, Li AF, Chi CW, Hsieh RH, Ku HH, Yeh TS. Notch2-in-duced COX-2 expression enhancing gastric cancer progression. Mol Carcinog 2012; 51: 939-951 [PMID: 21976141 DOI: 10.1002/mc.20865]
36. Bartchewsky W, Martini MR, Masiero M, Squassoni AC, Alvarez MC, Ladeira MS, Salvatore D, Trevisan M, Pedrazzoli J, Ribeiro ML. Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer. Scand J Gastroenterol 2009; 44: 153-161 [PMID: 18985541 DOI: 10.1080/00365520802530853]
37. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606 [PMID: 11179238]
38. Tan VP, Wong BC. Gastric cancer chemoprevention: the current evidence. Gastroenterol Clin North Am 2013; 42: 299-316 [PMID: 23639642 DOI: 10.1016/j.gtc.2013.02.001]
39. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-140 [PMID: 16491072 DOI: 10.1038/nrc1801]
40. Tanigawa T, Watanabe T, Higuchi K, Tominaga K, Fuji-wara Y, Oshitani N, Tarnawski AS, Arakawa T. Long-term use of nonsteroidal anti-inflammatory drugs normalizes the kinetics of gastric epithelial cells in patients with Heli-cobacter pylori infection via attenuation of gastric mucosal infammation. J Gastroenterol 2009; 44 Suppl 19: 8-17 [PMID: 19148787 DOI: 10.1007/s00535-008-2287-1]
41. Futagami S, Kawagoe T, Horie A, Shindo T, Hamamoto T, Suzuki K, Kusunoki M, Miyake K, Gudis K, Tsukui T, Crowe SE, Sakamoto C. Celecoxib inhibits apurinic/ apyrimidinic endonuclease-1 expression and prevents gastric cancer in Helicobacter pylori-infected mongolian gerbils. Digestion 2008; 78: 93-102 [PMID: 18987470 DOI: 10.1159/000167978]
42. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofe-coxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102 [PMID: 15713943 DOI: 10.1056/ NEJMoa050493]
43. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073 [PMID: 12383990 DOI: 10.1016/ S0140-6736(02)11131-7]
44. Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygen-ase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006; 37: 1725-1730 [PMID: 16728684 DOI: 10.1161/01. STR.0000226642.55207.94]
45. Lee KW, Bode AM, Dong Z. Molecular targets of phyto-chemicals for cancer prevention. Nat Rev Cancer 2011; 11: 211-218 [PMID: 21326325 DOI: 10.1038/nrc3017]
46. Foryst-Ludwig A, Neumann M, Schneider-Brachert W, Naumann M. Curcumin blocks NF-kappaB and the mo-togenic response in Helicobacter pylori-infected epithelial cells. Biochem Biophys Res Commun 2004; 316: 1065-1072 [PMID: 15044093 DOI: 10.1016/j.bbrc.2004.02.158]
47. Kundu P, De R, Pal I, Mukhopadhyay AK, Saha DR, Swarnakar S. Curcumin alleviates matrix metalloprotein-ase-3 and -9 activities during eradication of Helicobacter pylori infection in cultured cells and mice. PLoS One 2011; 6: e16306 [PMID: 21283694 DOI: 10.1371/journal. pone.0016306]
48. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, Mukhopadhyay AK. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Che-mother 2009; 53: 1592-1597 [PMID: 19204190 DOI: 10.1128/ AAC.01242-08]
49. Cai XZ, Wang J, Li XD, Wang GL, Liu FN, Cheng MS, Li F. Curcumin suppresses proliferation and invasion in human gastric cancer cells by downregulation of PAK1 activity and cyclin D1 expression. Cancer Biol Ther 2009; 8: 1360-1368 [PMID: 19448398 DOI: 10.4161/cbt.8.14.8720]
50. Lüer S, Troller R, Aebi C. Antibacterial and antiinfamma-tory kinetics of curcumin as a potential antimucositis agent in cancer patients. Nutr Cancer 2012; 64: 975-981 [PMID: 22973975 DOI: 10.1080/01635581.2012.713161]
51. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 1997; 94: 10367-10372 [PMID: 9294217]
52. Kohli P, Levy BD. Resolvins and protectins: mediating solutions to inflammation. Br J Pharmacol 2009; 158: 960-971 [PMID: 19594757 DOI: 10.1111/j.1476-5381.2009.00290.x]
53. Yanaka A, Fahey JW, Fukumoto A, Nakayama M, Inoue S, Zhang S, Tauchi M, Suzuki H, Hyodo I, Yamamoto M. Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans. Cancer Prev Res (Phila) 2009; 2: 353-360 [PMID: 19349290 DOI: 10.1158/1940-6207.CAPR-08-0192]
54. Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhäuser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001; 276: 32008-32015 PMID: 11410599 DOI: 10.1074/jbc. M104794200]
55. Lamb A, Yang XD, Tsang YH, Li JD, Higashi H, Hatakeya-ma M, Peek RM, Blanke SR, Chen LF. Helicobacter pylori CagA activates NF-kappaB by targeting TAK1 for TRAF6-mediated Lys 63 ubiquitination. EMBO Rep 2009; 10: 1242-1249 [PMID: 19820695 DOI: 10.1038/embor.2009.210]
56. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleu-kin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994; 29: 425-429 [PMID: 8036458]
57. Zhang MJ, Spite M. Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsatu-rated fatty acids. Annu Rev Nutr 2012; 32: 203-227 [PMID: 22404117 DOI: 10.1146/annurev-nutr-071811-150726]
58. Siddiqui RA, Harvey KA, Zaloga GP, Stillwell W. Modulation of lipid rafts by Omega-3 fatty acids in infammation and cancer: implications for use of lipids during nutrition support. Nutr Clin Pract 2007; 22: 74-88 [PMID: 17242459]
59. Hutton ML, Kaparakis-Liaskos M, Turner L, Cardona A, Kwok T, Ferrero RL. Helicobacter pylori exploits cholesterol-rich microdomains for induction of NF-kappaB-depen-dent responses and peptidoglycan delivery in epithelial cells. Infect Immun 2010; 78: 4523-4531 [PMID: 20713621 DOI: 10.1128/IAI.00439-10]
60. Correia M, Michel V, Matos AA, Carvalho P, Oliveira MJ, Ferreira RM, Dillies MA, Huerre M, Seruca R, Figueiredo C, Machado JC, Touati E. Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization. PLoS One 2012; 7: e35072 [PMID: 22529974 DOI: 10.1371/journal.pone.0035072]
61. Meier R, Wettstein A, Drewe J, Geiser HR. Fish oil (Eicosap-en) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001; 15: 851-855 [PMID: 11380323]
62. Kuriki K, Wakai K, Matsuo K, Hiraki A, Suzuki T, Yama-mura Y, Yamao K, Nakamura T, Tatematsu M, Tajima K. Gastric cancer risk and erythrocyte composition of docosa-hexaenoic acid with anti-infammatory effects. Cancer Epidemiol Biomarkers Prev 2007; 16: 2406-2415 [PMID: 18006930 DOI: 10.1158/1055-9965.EPI-07-0655]
63. Penner R, Fedorak RN, Madsen KL. Probiotics and nutra-ceuticals: non-medicinal treatments of gastrointestinal dis-eases. Curr Opin Pharmacol 2005; 5: 596-603 [PMID: 16214413 DOI: 10.1016/j.coph.2005.06.009]
64. Capurso G, Marignani M, Piciucchi M, Merola E, Delle Fave G. Probiotics and severe acute pancreatitis. J Clin Gastroen-terol 2008; 42 Suppl 3 Pt 1: S148-S151 [PMID: 18806709 DOI: 10.1097/MCG.0b013e318169e935]
65. Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Tao Y, De Simone C, Chang EB. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 2004; 127: 1474-1487 [PMID: 15521016]
66. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623 [PMID: 15479682 DOI: 10.1136/gut.2003.037747]
67. Patel A, Shah N, Prajapati JB. Clinical appliance of probiot-ics in the treatment of Helicobacter pylori infection-A brief review. J Microbiol Immunol Infect 2013 Jun 8. Epub ahead of print [PMID: 23757373 DOI: 10.1016/j.jmii.2013.03.010]
68. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, Song IS. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008; 13: 261-268 [PMID: 18665934 DOI: 10.1111/j.1523-5378.2008.00601.x]
69. Franceschi F, Cazzato A, Nista EC, Scarpellini E, Roccarina D, Gigante G, Gasbarrini G, Gasbarrini A. Role of probiotics in patients with Helicobacter pylori infection. Helicobacter 2007; 12 Suppl 2: 59-63 [PMID: 17991178 DOI: 10.1111/ j.1523-5378.2007.00565.x]
70. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Heli-cobacter pylori? Aliment Pharmacol Ther 2006; 23: 1077-1086 [PMID: 16611267 DOI: 10.1111/j.1365-2036.2006.02868.x]
71. Ryan KA, O'Hara AM, van Pijkeren JP, Douillard FP, O' Toole PW. Lactobacillus salivarius modulates cytokine induction and virulence factor gene expression in Heli-cobacter pylori. J Med Microbiol 2009; 58: 996-1005 [PMID: 19528183 DOI: 10.1099/jmm.0.009407-0]
72. Lee JS, Paek NS, Kwon OS, Hahm KB. Anti-infammatory actions of probiotics through activating suppressor of cyto-kine signaling (SOCS) expression and signaling in Helico-bacter pylori infection: a novel mechanism. J Gastroenterol Hepatol 2010; 25: 194-202 [PMID: 20136974 DOI: 10.1111/ j.1440-1746.2009.06127.x]
73. Yang YJ, Chuang CC, Yang HB, Lu CC, Sheu BS. Lacto-bacillus acidophilus ameliorates H. pylori-induced gastric inflammation by inactivating the Smad7 and NFκB pathways. BMC Microbiol 2012; 12: 38 [PMID: 22429929 DOI: 10.1186/1471-2180-12-38]
74. Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother 2011; 45: 960-966 [PMID: 21693698 DOI: 10.1345/aph.1Q104]
75. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analy-sis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 155-168 [PMID: 17229240 DOI: 10.1111/j.1365-2036.2006.03179.x]
76. Vítor JM, Vale FF. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunol Med Microbiol 2011; 63: 153-164 [PMID: 22077218 DOI: 10.1111/ j.1574-695X.2011.00865.x]
77. Mills JC, Shivdasani RA. Gastric epithelial stem cells. Gastroenterology 2011; 140: 412-424 [PMID: 21144849 DOI: 10.1053/j.gastro.2010.12.001]
78. Lin R, Ma H, Ding Z, Shi W, Qian W, Song J, Hou X. Bone marrow-derived mesenchymal stem cells favor the im-munosuppressive T cells skewing in a Helicobacter pylori model of gastric cancer. Stem Cells Dev 2013; 22: 2836-2848 [PMID: 23777268 DOI: 10.1089/scd.2013.0166]
79. Ding SZ, Zheng PY. Helicobacter pylori infection induced gastric cancer; advance in gastric stem cell research and the remaining challenges. Gut Pathog 2012; 4: 18 [PMID: 23217022 DOI: 10.1186/1757-4749-4-18]
80. Peek RM. Chronic Helicobacter pylori infection and DNA-damaged stem cells: a recipe for disaster. Dig Dis Sci 2013; 58: 13-16 [PMID: 23108565 DOI: 10.1007/s10620-012-2466-z]
81. Hardbower DM, de Sablet T, Chaturvedi R, Wilson KT. Chronic inflammation and oxidative stress: The smoking gun for Helicobacter pylori-induced gastric cancer? Gut Microbes 2013 Jun 28. Epub ahead of print [PMID: 23811829]
82. Xu H, Chaturvedi R, Cheng Y, Bussiere FI, Asim M, Yao MD, Potosky D, Meltzer SJ, Rhee JG, Kim SS, Moss SF, Hacker A, Wang Y, Casero RA, Wilson KT. Spermine oxidation induced by Helicobacter pylori results in apoptosis and DNA damage: implications for gastric carcinogen-esis. Cancer Res 2004; 64: 8521-8525 [PMID: 15574757 DOI: 10.1158/0008-5472.CAN-04-3511]
83. Chaturvedi R, Asim M, Romero-Gallo J, Barry DP, Hoge S, de Sablet T, Delgado AG, Wroblewski LE, Piazuelo MB, Yan F, Israel DA, Casero RA, Correa P, Gobert AP, Polk DB, Peek RM, Wilson KT. Spermine oxidase mediates the gastric cancer risk associated with Helicobacter pylori CagA. Gas-troenterology 2011; 141: 1696-1708.e1-2 [PMID: 21839041 DOI: 10.1053/j.gastro.2011.07.045]
84. Hahm KB, Lee KJ, Kim JH, Cho SW, Chung MH. Helico-bacter pylori infection, oxidative DNA damage, gastric carcinogenesis, and reversibility by rebamipide. Dig Dis Sci 1998; 43: 72S-77S [PMID: 9753230]
85. Hahm KB, Song YJ, Oh TY, Lee JS, Surh YJ, Kim YB, Yoo BM, Kim JH, Han SU, Nahm KT, Kim MW, Kim DY, Cho SW. Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible? J Bio-chem Mol Biol 2003; 36: 82-94 [PMID: 12542979]
86. Kim YJ, Kim EH, Hahm KB. Oxidative stress in infamma-tion-based gastrointestinal tract diseases: challenges and opportunities. J Gastroenterol Hepatol 2012; 27: 1004-1010 [PMID: 22413852 DOI: 10.1111/j.1440-1746.2012.07108.x]